Natera, Inc. (NTRA) stock
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30139% above fair value
$287.47−1.01 (-0.35%)
Close on Nov 17, 2026Market cap $41.44BP/E –Yield –
Natera r&d expenses
Research and development expenses are spending on new products and technology.
Natera's R&D Expenses for the twelve months ending Jun 30, 2026 was $787.38M, up 56.9% year over year. For fiscal 2025 it was $624.11M, up 54.4% from the year before. Over ten years it grew 36.5% a year on average. The highest annual figure on record is $624.11M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $624.11M | +54.4% |
| FY2024 | Dec 31, 2024 | $404.14M | +26.0% |
| FY2023 | Dec 31, 2023 | $320.68M | +1.3% |
| FY2022 | Dec 31, 2022 | $316.42M | +19.8% |
| FY2021 | Dec 31, 2021 | $264.21M | +164.1% |
| FY2020 | Dec 31, 2020 | $100.04M | +94.8% |
| FY2019 | Dec 31, 2019 | $51.36M | +0.0% |
| FY2018 | Dec 31, 2018 | $51.36M | +2.6% |
| FY2017 | Dec 31, 2017 | $50.06M | +19.6% |
| FY2016 | Dec 31, 2016 | $41.86M | +51.1% |
| FY2015 | Dec 31, 2015 | $27.71M | +60.3% |
| FY2014 | Dec 31, 2014 | $17.29M | +49.7% |
| FY2013 | Dec 31, 2013 | $11.55M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $228.07M | +55.8% |
| Q1 FY2026 | Mar 31, 2026 | $210.70M | +63.2% |
| Q4 FY2025 | Dec 31, 2025 | $175.19M | +35.3% |
| Q3 FY2025 | Sep 30, 2025 | $173.41M | +78.9% |
| Q2 FY2025 | Jun 30, 2025 | $146.43M | +64.3% |
| Q1 FY2025 | Mar 31, 2025 | $129.08M | +45.6% |
| Q4 FY2024 | Dec 31, 2024 | $129.46M | +56.0% |
| Q3 FY2024 | Sep 30, 2024 | $96.93M | +25.5% |
| Q2 FY2024 | Jun 30, 2024 | $89.11M | +14.0% |
| Q1 FY2024 | Mar 31, 2024 | $88.64M | +7.7% |
| Q4 FY2023 | Dec 31, 2023 | $82.96M | -5.6% |
| Q3 FY2023 | Sep 30, 2023 | $77.24M | +17.9% |
| Q2 FY2023 | Jun 30, 2023 | $78.17M | -5.3% |
| Q1 FY2023 | Mar 31, 2023 | $82.31M | +2.4% |
| Q4 FY2022 | Dec 31, 2022 | $87.91M | +22.4% |
| Q3 FY2022 | Sep 30, 2022 | $65.51M | -33.5% |
| Q2 FY2022 | Jun 30, 2022 | $82.58M | +53.6% |
| Q1 FY2022 | Mar 31, 2022 | $80.41M | +100.1% |
| Q4 FY2021 | Dec 31, 2021 | $71.81M | +121.7% |
| Q3 FY2021 | Sep 30, 2021 | $98.46M | +272.6% |
| Q2 FY2021 | Jun 30, 2021 | $53.75M | +133.7% |
| Q1 FY2021 | Mar 31, 2021 | $40.19M | +120.5% |
| Q4 FY2020 | Dec 31, 2020 | $32.38M | +115.9% |
| Q3 FY2020 | Sep 30, 2020 | $26.42M | +106.5% |
| Q2 FY2020 | Jun 30, 2020 | $23.01M | +89.7% |
| Q1 FY2020 | Mar 31, 2020 | $18.23M | +59.4% |
| Q4 FY2019 | Dec 31, 2019 | $15.00M | +17.5% |
| Q3 FY2019 | Sep 30, 2019 | $12.80M | +3.3% |
| Q2 FY2019 | Jun 30, 2019 | $12.12M | +2.3% |
| Q1 FY2019 | Mar 31, 2019 | $11.44M | -20.3% |
| Q4 FY2018 | Dec 31, 2018 | $12.77M | -1.9% |
| Q3 FY2018 | Sep 30, 2018 | $12.39M | -1.7% |
| Q2 FY2018 | Jun 30, 2018 | $11.85M | +0.6% |
| Q1 FY2018 | Mar 31, 2018 | $14.34M | +13.4% |
| Q4 FY2017 | Dec 31, 2017 | $13.02M | +13.6% |
| Q3 FY2017 | Sep 30, 2017 | $12.61M | +11.1% |
| Q2 FY2017 | Jun 30, 2017 | $11.79M | – |
| Q1 FY2017 | Mar 31, 2017 | $12.65M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.46M | – |
| Q3 FY2016 | Sep 30, 2016 | $11.35M | – |
See a number that looks wrong?